Literature DB >> 27323936

Investigating the early metabolic fingerprint of celiac disease - a prospective approach.

Franca F Kirchberg1, Katharina J Werkstetter1, Olaf Uhl1, Renata Auricchio2, Gemma Castillejo3, Ilma R Korponay-Szabo4, Isabel Polanco5, Carmen Ribes-Koninckx6, Sabine L Vriezinga7, Berthold Koletzko8, M Luisa Mearin7, Christian Hellmuth1.   

Abstract

OBJECTIVES AND STUDY: In the development of Celiac Disease (CD) both genetic and environmental factors play a crucial role. The Human Leukocyte Antigen (HLA)-DQ2 and HLA-DQ8 loci are strongly related to the disease and are necessary but not sufficient for the development of CD. Therefore, increasing interest lies in examining the mechanisms of CD onset from the early beginning. Differences in serum and urine metabolic profiles between healthy individuals and CD patients have been reported previously. We aimed to investigate if the metabolic pathways were already altered in young, 4 month old infants, preceding the CD diagnosis.
METHODS: Serum samples were available for 230 four month old infants of the PreventCD project, a multicenter, randomized, double-blind, dietary intervention study. All children were positive for HLA-DQ2 and/or HLA-DQ8 and had at least one first-degree relative diagnosed with CD. Amino acids were quantified after derivatization with liquid chromatography - tandem mass spectrometry (MS/MS) and polar lipid concentrations (acylcarnitines, lysophosphatidylcholines, phosphatidylcholines, and sphingomyelins) were determined with direct infusion MS/MS. We investigated the association of the metabolic profile with (1) the development of CD up to the age of 8 years (yes/no), (2) with HLA-risk groups, (3) with the age at CD diagnosis, using linear mixed models and cox proportional hazards models. Gender, intervention group, and age at blood withdrawal were included as potential confounder.
RESULTS: By the end of 2014, thirty-three out of the 230 children (14%) were diagnosed with CD according to the ESPGHAN criteria. Median age at diagnosis was 3.4 years (IQR, 2.4-5.2). Testing each metabolite for a difference in the mean between healthy and CD children, we (1) could not identify a discriminant analyte or a pattern pointing towards an altered metabolism (Bonferroni corrected P > 0.05 for all). Metabolite concentrations (2) did not differ across the HLA-risk groups. When investigating the age at diagnosis using (3) survival models, we found no evidence for an association between the metabolic profile and the risk of a later CD diagnosis.
CONCLUSION: The metabolic profile at 4 months of age was not predictive for the development of CD up to the age of 8 years. Our results suggest that metabolic pathways reflected in serum are affected only later in life and that the HLA-genotype does not influence the serum metabolic profile in young infants before introduction of solid food.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Celiac disease; Early programming; Human leukocyte antigen; Metabolomics

Mesh:

Substances:

Year:  2016        PMID: 27323936     DOI: 10.1016/j.jaut.2016.05.006

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  How Metabolomics Provides Novel Insights on Celiac Disease and Gluten-Free Diet: A Narrative Review.

Authors:  Mirco Vacca; Annalisa Porrelli; Francesco Maria Calabrese; Tamara Lippolis; Ilaria Iacobellis; Giuseppe Celano; Daniela Pinto; Francesco Russo; Gianluigi Giannelli; Maria De Angelis
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

2.  The impact of human breast milk components on the infant metabolism.

Authors:  Christian Hellmuth; Olaf Uhl; Hans Demmelmair; Maria Grunewald; Renata Auricchio; Gemma Castillejo; Ilma R Korponay-Szabo; Isabel Polanco; María Roca; Sabine L Vriezinga; Katharina J Werkstetter; Berthold Koletzko; M Luisa Mearin; Franca F Kirchberg
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

3.  Persistent Alterations in Plasma Lipid Profiles Before Introduction of Gluten in the Diet Associated With Progression to Celiac Disease.

Authors:  Partho Sen; Cecilia Carlsson; Suvi M Virtanen; Satu Simell; Heikki Hyöty; Jorma Ilonen; Jorma Toppari; Riitta Veijola; Tuulia Hyötyläinen; Mikael Knip; Matej Orešič
Journal:  Clin Transl Gastroenterol       Date:  2019-05-22       Impact factor: 4.488

4.  Alterations in One-Carbon Metabolism in Celiac Disease.

Authors:  Rafael Martín-Masot; Natàlia Mota-Martorell; Mariona Jové; José Maldonado; Reinald Pamplona; Teresa Nestares
Journal:  Nutrients       Date:  2020-12-02       Impact factor: 5.717

5.  Preserved central cholinergic functioning to transcranial magnetic stimulation in de novo patients with celiac disease.

Authors:  Giuseppe Lanza; Francesco Fisicaro; Carmela Cinzia D'Agate; Raffaele Ferri; Mariagiovanna Cantone; Luca Falzone; Giovanni Pennisi; Rita Bella; Marios Hadjivassiliou; Manuela Pennisi
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

6.  Metabolic heterogeneity caused by HLA-DRB1*04:05 and protective effect of inosine on autoimmune hepatitis.

Authors:  Fan Yang; Leyu Zhou; Yi Shen; Shenglan Zhao; Yanyi Zheng; Ruoting Men; Xiaoli Fan; Li Yang
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

7.  Up-Regulation of Specific Bioactive Lipids in Celiac Disease.

Authors:  Rafael Martín-Masot; Jose Daniel Galo-Licona; Natàlia Mota-Martorell; Joaquim Sol; Mariona Jové; José Maldonado; Reinald Pamplona; Teresa Nestares
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

8.  A Phospholipid Profile at 4 Months Predicts the Onset of Celiac Disease in at-Risk Infants.

Authors:  R Auricchio; M Galatola; D Cielo; A Amoresano; M Caterino; E De Vita; A Illiano; R Troncone; L Greco; M Ruoppolo
Journal:  Sci Rep       Date:  2019-10-04       Impact factor: 4.379

Review 9.  Molecular Biomarkers for Celiac Disease: Past, Present and Future.

Authors:  Aarón D Ramírez-Sánchez; Ineke L Tan; B C Gonera-de Jong; Marijn C Visschedijk; Iris Jonkers; Sebo Withoff
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.